A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

NCT06049927 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3300

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Influenza

Interventions

BIOLOGICAL: Quadrivalent influenza vaccine(0.25ml)
BIOLOGICAL: Quadrivalent influenza vaccine(0.5ml)
BIOLOGICAL: Trivalent influenza vaccine(BV)
BIOLOGICAL: Trivalent influenza vaccine(BY)

Sponsor

Sinovac Biotech Co., Ltd